Freeform Search

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: 20030138772

Display: 100 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search Clear Interrupt

Search History

DATE: Friday, November 18, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L13	(TR$ or ITR$) near10 (chimeric or hybrid$ or artificial) near10 capsid$	5	L13
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L12	L11 and TR$ near10 cap$	2	L12
L11	20040180440	2	L11
L10	l1 and rep near10 AAV2	1	L10
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L9	L1 and (AAV5 or AAV-5)	1	L9
L8	L1 and (AAV1 or AAV-1)	1	L8
L7	L1 and tissue	1	L7
L6	L1 and therapeutic	1	L6
L5	L1 and insect$	1	L5
L4	L1 and (adenovir$ or helper or accessory)	1	L4
L3	L1 and capsid$	2	L3
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			

L2	l1 and antibod$	1	L2
L1	20030138772	2	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L11 and second near20 librar$	2

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L17

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Friday, November 18, 2005 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L17	L11 and second near20 librar$	2	L17
L16	L11 and second	2	L16
L15	l11 and second near20 "not"	0	L15
L14	l11 and second near10 "not"	0	L14
L13	(TR$ or ITR$) near10 (chimeric or hybrid$ or artificial) near10 capsid$	5	L13
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L12	L11 and TR$ near10 cap$	2	L12
L11	20040180440	2	L11
L10	l1 and rep near10 AAV2	1	L10
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L9	L1 and (AAV5 or AAV-5)	1	L9
L8	L1 and (AAV1 or AAV-1)	1	L8

L7	L1 and tissue	1	L7
L6	L1 and therapeutic	1	L6
L5	L1 and insect$	1	L5
L4	L1 and (adenovir$ or helper or accessory)	1	L4
L3	L1 and capsid$	2	L3
DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L2	l1 and antibod$	1	L2
L1	20030138772	2	L1

END OF SEARCH HISTORY

```
      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,6,55,154,155,156,312,399,biotech,biosci
```

```
      Set  Items  Description
      ---  -----  -----------
? s (AAV? or adeno (n) associated) and cap (5n) (hybrid? or chimeric)
Processed  10 of  39 files ...
Processing
Completed processing all files
          20190  AAV?
          64538  ADENO
        8688626  ASSOCIATED
          28103  ADENO(N)ASSOCIATED
         190820  CAP
        2398312  HYBRID?
         229623  CHIMERIC
            531  CAP(5N)(HYBRID? OR CHIMERIC)
      S1     41  (AAV? OR ADENO (N) ASSOCIATED) AND CAP (5N) (HYBRID? OR
                 CHIMERIC)
? rd s1
>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
      S2     10  RD S1 (unique items)
? s s2 not py>2002
>>>One or more prefixes are unsupported
>>>  or undefined in one or more files.
             10  S2
       19607638  PY>2002
      S3      6  S2 NOT PY>2002
? d s3/3/1-6
      Display 3/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0013099726   BIOSIS NO.: 200100271565
Recombinant adenovirus expressing adeno-associated virus cap
  and rep proteins supports production of high-titer recombinant
  adeno-associated virus
AUTHOR: Zhang H-G; Wang Y M; Xie J F; Liang X; Hsu H-C; Zhang X; Douglas J;
  Curiel D T; Mountz J D (Reprint)
AUTHOR ADDRESS: Department of Medicine, Division of Clinical Immunology and
  Rheumatology, University of Alabama at Birmingham, 701 South 19th Street,
  LHRB 473, Birmingham, AL, 35294, USA**USA
JOURNAL: Gene Therapy  8 (9): p704-712 May, 2001 2001
MEDIUM: print
ISSN: 0969-7128
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

                                - end of record -
? d s3/9/1-6
      Display 3/9/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0013099726   BIOSIS NO.: 200100271565
Recombinant adenovirus expressing adeno-associated virus cap
  and rep proteins supports production of high-titer recombinant
  adeno-associated virus
AUTHOR: Zhang H-G; Wang Y M; Xie J F; Liang X; Hsu H-C; Zhang X; Douglas J;
  Curiel D T; Mountz J D (Reprint)
AUTHOR ADDRESS: Department of Medicine, Division of Clinical Immunology and
  Rheumatology, University of Alabama at Birmingham, 701 South 19th Street,
  LHRB 473, Birmingham, AL, 35294, USA**USA
JOURNAL: Gene Therapy  8 (9): p704-712 May, 2001 2001
MEDIUM: print
ISSN: 0969-7128
```

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

-more-

?
Display 3/9/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

ABSTRACT: It has been difficult to produce a chimeric vector containing both Ad and **AAV** rep and **cap**, and to grow such **chimeric** vectors in 293 cells. By recombination in vitro in a bacterial host, we were able to produce recombinant plasmid AdAAV (pAdAAVrep-cap), which could be used to generate recombinant AdAAV (rAdAAVrep-cap) after transfection into 293 cells. A recombinant adenovirus, rAdAAVGFP, in which the green fluorescent protein (GFP) gene is flanked by the **AAV** terminal repeats cloned into the E1-deleted site of Ad was also generated. Co-infection of rAdAAVrep-cap together with rAdAAVGFP into 293 cells resulted in production of high titers of rAAV expressing GFP. It was noted that the titer of rAdAAVrep-cap was lower than the titer of control AdCM-VLacZ. The lower titer of rAdAAvrep-cap was associated with expression of Rep protein. Non-homologous recombination occurs after high passage and results in deletions within the ***AAV*** rep genes. These results indicate that (1) rAdAAVrep-cap can be produced; (2) rAdAAVrep-cap + rAdAAVGFP is a convenient and efficient way to transfect 293 cells to grow high titer rAAV; and (3) frozen stock is required to

-more-

?
Display 3/9/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

avoid propagation of rep-deleted pAdAAVrep-cap.

DESCRIPTORS:
MAJOR CONCEPTS: Molecular Genetics--Biochemistry and Molecular Biophysics ; Methods and Techniques
BIOSYSTEMATIC NAMES: Adenoviridae--dsDNA Viruses, Viruses, Microorganisms ; Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Parvoviridae--ssDNA Viruses, Viruses, Microorganisms
ORGANISMS: adenovirus (Adenoviridae)--recombinant; 293 cell line (Hominidae); **adeno-associated** virus (Parvoviridae)--high-titer, recombinant
COMMON TAXONOMIC TERMS: Double-Stranded DNA Viruses; Animals; Chordates; Humans; Mammals; Primates; Vertebrates; Single-Stranded DNA Viruses; Microorganisms; Viruses
CHEMICALS & BIOCHEMICALS: cap protein; rep protein
GENE NAME: **adeno-associated** virus cap gene (Parvoviridae); **adeno-associated** virus rep gene (Parvoviridae)

-more-

?
Display 3/9/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

METHODS & EQUIPMENT: transfection--gene transfer method
CONCEPT CODES:
33506 Virology - Animal host viruses
02508 Cytology - Human
03502 Genetics - General
03508 Genetics - Human
31500 Genetics of bacteria and viruses
BIOSYSTEMATIC CODES:
03116 Adenoviridae
86215 Hominidae
03205 Parvoviridae

- end of record -

?
Display 3/9/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0012994988 BIOSIS NO.: 200100166827
Monoclonal antibody specifically recognizing **adeno-associated** virus cap protein
AUTHOR: Shimada Takashi (Reprint); Kuma Hidekazu; Suzuki Yosuke
AUTHOR ADDRESS: Tokyo, Japan**Japan
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1236 (4): July 25, 2000 2000
MEDIUM: e-file
PATENT NUMBER: US 6093534 PATENT DATE GRANTED: July 25, 2000 20000725
PATENT CLASSIFICATION: 435-5 PATENT ASSIGNEE: Hisamitsu Pharmaceutical Co., Inc., Saga, Japan PATENT COUNTRY: USA
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

-more-
?
Display 3/9/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

ABSTRACT: A monoclonal antibody specifically recognizing **adeno-associated** virus **CAP** protein, which is produced by **hybridomas** obtained by fusing lymphocytes prepared from a mammal which has been immunized with the **adeno-associated** virus CAP protein or a recombinant thereof as an antigen with a myeloma cell line. The monoclonal antibody of the present invention is a novel antibody and capable of specifically recognizing the **adeno-associated** virus CAP protein. Thus, it is applicable to the detection of the **adeno-associated** virus and the purification of **adeno-** ***associated*** virus vectors for gene therapy.

DESCRIPTORS:
MAJOR CONCEPTS: Clinical Immunology--Human Medicine, Medical Sciences
CHEMICALS & BIOCHEMICALS: **adeno-associated** virus cap protein; monoclonal antibody
METHODS & EQUIPMENT: gene therapy--genetic method, recombinant gene expression applications

-more-
?
Display 3/9/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

CONCEPT CODES:
00532 General biology - Miscellaneous

- end of record -
?
Display 3/9/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011753004 BIOSIS NO.: 199900012664
High-titer **adeno-associated** viral vectors from a Rep/**Cap** cell line and **hybrid** shuttle virus
AUTHOR: Gao Guang-Ping; Qu Guang; Faust Lynn Z; Engdahl Ryan K; Xiao Weidong; Hughes Joseph V; Zoltick Philip W; Wilson James M (Reprint)
AUTHOR ADDRESS: 204 Wistar Inst., 3601 Spruce St., Philadelphia, PA 19104-4268, USA**USA
JOURNAL: Human Gene Therapy 9 (16): p2353-2362 Nov. 1, 1998 1998
MEDIUM: print
ISSN: 1043-0342

DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: **Adeno-associated** virus (**AAV**) is a potential vector for in vivo gene therapy. A critical analysis of its utility has

-more-

?

Display 3/9/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

been hampered by methods of production that are inefficient, difficult to scale up, and that often generate substantial quantities of replication-competent ***AAV*** . We describe a novel method for producing ***AAV*** that addresses these problems. A cell line, called B50, was created by stably transfecting into HeLa cells a rep/cap-containing plasmid utilizing endogenous ***AAV*** promoters. Production of ***AAV*** occurs in a two-step process. B50 is infected with an adenovirus defective in E2b, to induce Rep and Cap expression and provide helper functions, followed by a hybrid virus in which the **AAV** vector is cloned in the E1 region of a replication-defective adenovirus. This results in a 100-fold amplification and rescue of the **AAV** genome, leading to a high yield of recombinant **AAV** that is free of replication-competent ***AAV*** . Intramuscular injection of vector encoding erythropoietin into skeletal muscle of mice resulted in supraphysiologic levels of hormone in serum that was sustained and caused polycythemia. This method of ***AAV*** production should be useful in scaling up for studies in large animals, including humans.

-more-

?

Display 3/9/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

REGISTRY NUMBERS: 11096-26-7: erythropoietin
DESCRIPTORS:
MAJOR CONCEPTS: Blood and Lymphatics--Transport and Circulation; Methods and Techniques; Molecular Genetics--Biochemistry and Molecular Biophysics
BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia; Parvoviridae--ssDNA Viruses, Viruses, Microorganisms
ORGANISMS: mouse (Muridae)--animal model; B50 cell line (Muridae); **adeno-associated** virus (Parvoviridae)--gene vector, intramuscular administration
COMMON TAXONOMIC TERMS: Animals; Chordates; Mammals; Nonhuman Vertebrates ; Nonhuman Mammals; Rodents; Vertebrates; Single-Stranded DNA Viruses; Microorganisms; Viruses
DISEASES: polycythemia--blood and lymphatic disease
MESH TERMS: Polycythemia (MeSH)
CHEMICALS & BIOCHEMICALS: erythropoietin--serum; Cap; Rep

-more-

?

Display 3/9/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

METHODS & EQUIPMENT: **adeno-associated** viral vector production --genetic method; gene therapy--therapeutic method
CONCEPT CODES:
31500 Genetics of bacteria and viruses
02506 Cytology - Animal
03506 Genetics - Animal
10060 Biochemistry studies - General
12512 Pathology - Therapy
15001 Blood - General and methods
BIOSYSTEMATIC CODES:

. 86375 Muridae
  03205 Parvoviridae

- end of record -

?
Display 3/9/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0007096551 BIOSIS NO.: 199089014442
CONSTRUCTION OF A RECOMBINANT HUMAN PARVOVIRUS B19 **ADENO-ASSOCIATED** VIRUS 2 **AAV** DNA INVERTED TERMINAL REPEATS ARE FUNCTIONAL IN AN **AAV**-B19 HYBRID VIRUS
AUTHOR: SRIVASTAVA C H (Reprint); SAMULSKI R J; LU L; LARSEN S H; SRIVASTAVA A
AUTHOR ADDRESS: DEP MICROBIOL AND IMMUNOL, INDIANA UNIV SCH OF MED, 635 BARNHILL DRIVE, INDIANAPOLIS, INDIANA 46202, USA**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 86 (20): p8078-8082 1989
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: To facilitate genetic analysis of the human pathogenic parvovirus

-more-

?
Display 3/9/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

B19, we constructed a hybrid B19 viral genome in which the defective B19 inverted terminal repeats were replaced with the full-length inverted terminal repeats from a nonpathogenic human parvovirus, the **adeno-** ***associated*** virus 2 (***AAV***). The hybrid ***AAV*** -B19 genome was rescued from a recombinant plasmid and then the DNA was replicated upon transfection into adenovirus 2-infected human KB cells in the presence of **AAV** genes coding for proteins required for **AAV** DNA replication (***AAV*** -Rep proteins). In addition, in the presence of **AAV** genes coding for the viral capsid proteins (**AAV-Cap** proteins), the rescued/replicated **hybrid AAV**-B19 genomes were packaged into mature **AAV** progeny virions, which were subsequently released into culture supernatants. The recombinant ***AAV*** -B19 progeny virions were infectious for normal human bone marrow cells and strongly suppressed erythropoiesis in vitro. The availability of an infectious recombinant B19 virus should facilitate the mutational analysis of the viral genome, which, in turn, may yield information on individual viral gene functions in B19-induced pathogenesis. The hybrid ***AAV*** -B19

-more-

?
Display 3/9/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

genome may also prove to be a useful vector for gene transfer in human bone marrow cells.

DESCRIPTORS: BONE MARROW CELLS ERYTHROPOIESIS GENE TRANSFER VECTOR
DESCRIPTORS:
  MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and Lymphatics--Transport and Circulation; Cell Biology; Genetics; Microbiology
  BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
  COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates; Vertebrates
CONCEPT CODES:
  02508 Cytology - Human

. 03508 Genetics - Human
  10052 Biochemistry methods - Nucleic acids, purines and pyrimidines
  10062 Biochemistry studies - Nucleic acids, purines and pyrimidines

-more-

?
      Display 3/9/4   (Item 4 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.
  10506 Biophysics - Molecular properties and macromolecules
  15004 Blood - Blood cell studies
  15008 Blood - Lymphatic tissue and reticuloendothelial system
  31500 Genetics of bacteria and viruses
  33506 Virology - Animal host viruses
BIOSYSTEMATIC CODES:
  86215 Hominidae

- end of record -

?
      Display 3/9/5   (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2005 American Chemical Society. All rts. reserv.

  130292438   CA: 130(22)292438q   PATENT
  Chimeric AAV/B19 parvovirus-based recombinant vector system specifically
targeting the erythroid lineage
  INVENTOR(AUTHOR): Srivastava, Arun; Ponnazhagan, Selvarangan
  LOCATION: USA
  ASSIGNEE: Advanced Research and Technology Institute
  PATENT: PCT International ; WO 9918227 A1 DATE: 19990415
  APPLICATION: WO 98US21202 (19981008) *US 61364 (19971008)
  PAGES: 76 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/86A;
C12N-015/35B; C12N-007/01B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA;
BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; HR;
HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG;
MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR;
TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
  DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY;
DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;

-more-

?
      Display 3/9/5   (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2005 American Chemical Society. All rts. reserv.
CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
  SECTION:
CA203002 Biochemical Genetics
CA210XXX MICROBIAL, ALGAL, AND FUNGAL BIOCHEMISTRY
  IDENTIFIERS: AAV B19 parvovirus vector chimera cloning gene therapy,
sequence AAV promoter vector chimera
  DESCRIPTORS:
Hemoglobins...
    α, β, and γ chain cloning and gene therapy; chimeric
    AAV/B19 parvovirus-based recombinant vector system specifically
    targeting the erythroid lineage
c-myb gene(animal)... c-myc gene(animal)... c-src gene(animal)...
Oncogenes(animal)... ras gene(animal)...
    antisense RNA to; for gene therapy; chimeric AAV/B19 parvovirus-based
    recombinant vector system specifically targeting the erythroid lineage
Capsid...
    B19; chimeric AAV/B19 parvovirus-based recombinant vector system

-more-

?
      Display 3/9/5   (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2005 American Chemical Society. All rts. reserv.

specifically targeting the erythroid lineage
Genes(microbial)...
cap, B19; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Adeno-associated virus... Bone marrow... B19 virus... DNA sequences...
Enhancer(genetic element)... Erythroid precursor cell... Gene therapy...
Heart... Molecular cloning... Monocyte... Transformation(genetic)...
Vascular endothelium... Virus vectors...
chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Antisense RNA... Interleukin 10... Interleukin 11... Interleukin 1...
Interleukin 2... Interleukin 3... Interleukin 4... Interleukin 5...
Interleukin 6... Interleukin 7... Interleukin 8... Interleukin 9...
p53(protein)... Rb protein... Stem cell factor... Tumor necrosis factors...
cloning and gene therapy; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Promoter(genetic element)...

-more-

?
Display 3/9/5 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

CMV IE, LTR, SV40 IE, HSV tk, β-actin, b19p6, or human globin; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Genes(animal)...
erb; antisense RNA to; for gene therapy; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Proteins(specific proteins and subclasses)...
p21, cloning and gene therapy; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Genes(animal)...
raf, antisense RNA to; for gene therapy; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Genes(microbial)...
rep, AAV; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage

-more-

?
Display 3/9/5 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

Inverted repeat(DNA)...
terminal; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
Genes(microbial)...
VP1, B19; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
CAS REGISTRY NUMBERS:
9004-10-8P biological studies, cloning and gene therapy; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
9014-00-0P 9026-93-1P 9027-80-9P 83869-56-1P cloning and gene therapy; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
223121-09-3 nucleotide sequence; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the erythroid lineage
1404-04-2 resistance; cloning and gene therapy; chimeric AAV/B19 parvovirus-based recombinant vector system specifically targeting the

-more-

?
Display 3/9/5 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

(c) 2005 American Chemical Society. All rts. reserv.
erythroid lineage

- end of record -

?
Display 3/9/6 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0203939 DBR Accession Number: 96-14710 PATENT
Monoclonal antibody specific for **adeno-associated** virus CAP protein - by hybridoma cell culture for adeno helper virus detection and gene therapy
AUTHOR: Shimada T; Kuma H; Suzuki Y
CORPORATE SOURCE: Saga, Japan.
PATENT ASSIGNEE: Hisamitsu-Pharm. 1996
PATENT NUMBER: WO 9629349 PATENT DATE: 960926 WPI ACCESSION NO.: 96-443139 (9644)
PRIORITY APPLIC. NO.: JP 9559149 APPLIC. DATE: 950317
NATIONAL APPLIC. NO.: WO 96JP655 APPLIC. DATE: 960315
LANGUAGE: JA
ABSTRACT: A monoclonal antibody (MAb) specific for **adeno-associated** virus (**AAV**) vector CAP protein is new and is produced by a hybridoma formed by the fusion of lymphocytes from mammals immunized with a recombinant **AAV** CAP protein, and a

-more-

?
Display 3/9/6 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.
myeloma cell. Also claimed is and a method for producing recombinant ***AAV*** CAP protein. The MAb may be used to detect adeno helper virus and may be used in gene therapy. In an example, the spleens of mice immunized with WA0322-1 were removed and washed first in phosphate buffer containing kanamycin, and then in RPMI 1640 medium, after which the cells were prepared for hybridization. Spleen cells and mouse myeloma cells P3-X63-Ag8.U1 (P3U1) were mixed in a ratio of 5:1, and after the medium was removed, 1 ml of PEG-400 was added and incubated at 37 deg for 2 min. The cells were then washed in RPMI 1640 medium and resuspended in HAT medium. The cells were placed in wells and incubated for 7 days with the addition of extra HAT medium after 3 days. The supernatant was tested for reaction to WA0322-1 by ELISA and positive cells were taken for primary cloning. 7 Hybridoma lines were obtained (1E7, 1E9, 1G5, 1G12, 2H7, 2H9 and 3E7). (128pp)
DESCRIPTORS: recombinant **adeno-associated** virus vector ***CAP*** monoclonal antibody prepare, ***hybridoma*** cell culture, appl. adeno virus helper virus determine, gene therapy parvo virus antibody

-more-

?
Display 3/9/6 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.
engineering (Vol.15, No.25)
SECTION: PHARMACEUTICALS-Antibodies; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology; CELL CULTURE-Animal Cell Culture (D6,A1,J1)

- end of record -

?
? s VP1 (5n) different (5n) (VP2 or VP3)
21538 VP1
11158935 DIFFERENT
13550 VP2
8603 VP3
S4 173 VP1 (5N) DIFFERENT (5N) (VP2 OR VP3)
? s s4 and AAV?
173 S4

```
          20190  AAV?
      S5      1  S4 AND AAV?
? d s5/9/1
      Display 5/9/1     (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.

0247255  DBR Accession Number: 2000-01745
Chimeric virus-like particle formation of adeno-associated virus - the
    capsids of which are composed of three proteins, VP1, VP2, and VP3
AUTHOR: Hoque M;  Shimizu N;  Ishizu K;  Yajima H;  Arisaki F;  Suzuki K;
    Watanabe H; +Handa H
CORPORATE AFFILIATE: Tokyo-Inst.Technol.  Nat.Inst.Infec.Dis.Tokyo
CORPORATE SOURCE: Frontier Collaborative Research Laboratory, Tokyo
    Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama,
    226-8501, Japan. email:hhanda@bio.titech.ac.jp
JOURNAL: Biochem.Biophys.Res.Commun.  (266, 2, 371-76)  1999
ISSN: 0006-291X  CODEN: BBRCA9
LANGUAGE: English
ABSTRACT:  Adeno-associated virus (AAV) capsids are composed of three
    proteins, VP1, VP2, and VP3 which have a common amino
     acid  sequence, being expressed from different initiation codons
    on  the  same  open  reading frame. Although VP1 is necessary for viral

                                    -more-
?
      Display 5/9/1     (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.
    infection,  it  is  not  essential  for  capsid  formation.  The capsid
    proteins  VP2  and  VP3  are sufficient for capsid formation, but their
    functions are poorly understood. To investigate the roles of the capsid
    proteins  in capsid formation, a baculo virus protein expression system
    was  used to produce virus-like particles (VLPs). Varying the ratios of
    VP2  and  VP3  did  not  affect  VLP formation. Further, their physical
    properties  were  equivalent to those of empty wild-type particles. The
    function  of  VP3  was  studied  by  fusing a peptide tag, FLAG, to its
    N-terminus. This chimeric viral protein, in combination with VP2, could
    assemble into VLPs, indicating that the chimerism of VP3 did not affect
     the  VLP  formation.  It  may  be possible to utilize  ***AAV***  VLP as
    vectors  of  a  broad  range  of  drugs  since  the  fusion  of the VP3
    N-terminus with defined molecules could impose distinct physical
    properties onto the internal environment of the VLP. (21 ref)
DESCRIPTORS: adeno-associated virus, capsid formation, baculo virus protein
    expression system, virus-like particle chimerism, appl. drug delivery
    parvo virus gene therapy (Vol.19, No.4)

                                    -more-
?
      Display 5/9/1     (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.
SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING
    AND FERMENTATION-Nucleic Acid Technology  (D7,A1)

                                - end of record -
? s s4 and adeno
           173  S4
         64538  ADENO
      S6      3  S4 AND ADENO
? d s6/9/1-3
      Display 6/9/1     (Item 1 from file: 24)
DIALOG(R)File  24:CSA Life Sciences Abstracts
(c) 2005 CSA. All rts. reserv.

0001530716       IP ACCESSION NO: 3792318
The recognition of parvovirus capsids by antibodies
```

Agbandje, M; Parrish, CR; Rossmann, MG
Dep. Biol. Sci., Purdue University, West Lafayette, IN 47907-1392, USA

Seminars in Virology, v 6, n 4, p 219-231, 1995
ADDL. SOURCE INFO: Seminars in Virology [SEMIN. VIROL.], volume 6, number 4, pp. 219-231, 1995
PUBLICATION DATE: 1995

DOCUMENT TYPE: Journal Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English
ISSN: 1044-5773

-more-

?

Display 6/9/1 (Item 1 from file: 24)
DIALOG(R)File 24:CSA Life Sciences Abstracts

FILE SEGMENT: Virology & AIDS Abstracts; Immunology Abstracts

ABSTRACT:
The parvoviruses are small, non-enveloped icosahedral viruses which infect many animals, including vertebrates and arthropods. Vertebrate parvoviruses can be classified into the autonomous and the **adeno** -associated viruses; the autonomous parvoviruses have been examined in detail for antigenic structure. The protective immunity against parvoviruses in animals appears to be primarily antibody-mediated. The capsid of the autonomous parvoviruses is assembled from two proteins, VP1 and VP2, which overlap in sequence, with VP1 having additional N-terminal residues. Empty capsids can be assembled from VP2 alone. The structures of canine parvovirus (CPV) and feline panleukopenia virus (FPV) have been solved to better than 3.5 angstrom resolution, and the structure of human parvovirus, B19, has been solved to 8 angstrom resolution. In each case the T = 1 icosahedron is made up to 60 copies of a structural motif common to VP1 and VP2, consisting of an eight-stranded anti-parallel beta -barrel.

-more-

?

Display 6/9/1 (Item 1 from file: 24)
DIALOG(R)File 24:CSA Life Sciences Abstracts

The surface of the capsid is made up primarily of large elaborate loops which connect the beta -strands that make up the barrel. Antigenic epitopes have been mapped utilizing escape mutants, natural variants, peptide analysis and by expression of viral proteins. In CPV two major antigenic determinants were defined by escape mutant analysis, while peptide analysis revealed antigenic determinants in many **different** regions of the capsid protein, including the amino terminus of ***VP2*** . Neutralizing epitopes of B19 were found by peptide analysis in the **VP1**-unique region and in sequences common to ***VP1*** and ***VP2*** . Other antigenic, but non-neutralizing, epitopes were found in the **VP1-VP2** junction, as well as various other parts of the ***VP2*** protein. The binding of an Fab derived from one neutralizing anti-CPV Mab has been examined by cryo-electron microscopy image reconstruction, that showed 60 copies of the Fab were bound per virion. The Fab footprint covered approximately 796 angstrom super(2) of the capsid surface, in a region where escape mutations to that Mab previously had been shown to cluster. The mechanism of neutralization was not clear, but could involve

-more-

?

Display 6/9/1 (Item 1 from file: 24)
DIALOG(R)File 24:CSA Life Sciences Abstracts

interference with cell attachment, cell entry or uncoating during the process of cell infection.

DESCRIPTORS: antibodies; capsids; parvovirus
SUBJ CATG: 22093, Antigen-antibody interaction; 06002, Viruses

- end of record -

?
Display 6/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

04293534 Genuine Article#: RU694 Number of References: 49
Title: THE RECOGNITION OF PARVOVIRUS CAPSIDS BY ANTIBODIES
Author(s): AGBANDJE M; PARRISH CR; ROSSMANN MG
Corporate Source: PURDUE UNIV,DEPT BIOL SCI/W LAFAYETTE//IN/47907; CORNELL UNIV,NEW YORK STATE COLL VET MED,JAMES A BAKER INST ANIM HLTH/ITHACA//NY/14853
Journal: SEMINARS IN VIROLOGY, 1995, V6, N4 (AUG), P219-231
ISSN: 1044-5773
Language: ENGLISH Document Type: ARTICLE
Geographic Location: USA
Subfile: SciSearch; CC LIFE--Current Contents, Life Sciences
Journal Subject Category: VIROLOGY
Abstract: The parvoviruses are small, non-enveloped icosahedral viruses which infect many animals, including vertebrates and arthropods. Vertebrate parvoviruses can be classified into the autonomous and the **adeno**-associated viruses; the autonomous parvoviruses have been

-more-

?
Display 6/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

examined in detail for antigenic structure. The protective immunity against parvoviruses in animals appears be primarily to antibody-mediated. The capsid of the autonomous parvoviruses is assembled from two proteins, VP1 and VP2, which overlap in sequence, with VP1 having additional N-terminal residues. Empty capsids can be assembled from VP2 alone.

The structures of canine parvovirus (CPV) and feline panleukopenia virus (FPV) have been solved to better than 3.5 Angstrom resolution, and the structure of human parvovirus; B19, has been solved to 8 Angstrom resolution. In each case the T = 1 icosahedron is made up to 60 copies of a structural motif common to VP1 and VP2, consisting of an eight-stranded anti-parallel beta-barrel. The surface of the capsid is made up primarily of large elaborate loops which connect the beta-strands that make up the barrel. Antigenic epitopes have been mapped utilizing escape mutants, natural variants, peptide analysis and by expression of viral proteins. In CPV two major antigenic

-more-

?
Display 6/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

determinants were defined by escape mutant analysis, while peptide analysis revealed antigenic determinants in many **different** regions of the capsid protein, including the amino terminus of ***VP2*** . Neutralizing epitopes of B19 were found by peptide analysis in the **VP1**-unique region and in sequences common to VPI and ***VP2*** . Other antigenic, but non-neutralizing; epitopes were found in the **VP1**-**VP2** junction, as well as various other parts of the ***VP2*** protein.

The binding of an Fab derived from one neutralizing anti-CPV Mab has been examined by cryo-electron microscopy image reconstruction that showed 60 copies of the Fab were bound per virion. The Fab footprint covered approximately 736 Angstrom(2) of the capsid surface, in a region where escape mutations to that Mab previously had been shown to

cluster: The mechanism of neutralization was not clear but could involve interference with cell attachment, cell entry or uncoating during the process of cell infection.

-more-

?

Display 6/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

Descriptors--Author Keywords: PARVOVIRUSES ; ANTIGENIC EPITOPES ; X-RAY ; CRYSTALLOGRAPHY
Identifiers--KeyWords Plus: B-CELL EPITOPES; CANINE PARVOVIRUS; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; PROTEIN STRUCTURES; SURFACE; REGION; VIRUS; SEQUENCE; IDENTIFICATION
Research Fronts: 93-0090 002 (ANGSTROM RESOLUTION; REFINED CRYSTAL-STRUCTURE; ESCHERICHIA-COLI HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN HPR)
93-0763 001 (SYNTHETIC PEPTIDE COMBINATORIAL LIBRARIES; EXPRESSION OF IMMUNOGLOBULIN FAB FRAGMENTS; BUILDING ANTIBODIES)
93-0785 001 (PARVOVIRUS B19 INFECTION; POLYMERASE CHAIN-REACTION; RAPID DETECTION)
93-0967 001 (PROTEIN FOLDING; STRUCTURAL ENERGETICS OF THE MOLTEN GLOBULE STATE; HYDROPHOBIC CORE; SIMILAR THERMODYNAMIC STABILITY)
93-3786 001 (CAPSID PROTEIN; RNA VIRUSES; TEMPERATURE-SENSITIVE MUTATIONS)
Cited References:

-more-

?

Display 6/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

AGBANDJE M, 1993, V16, P155, PROTEINS
AGBANDJE M, 1994, V203, P106, VIROLOGY
ANDERSON LJ, 1989, V321, P536, NEW ENGL J MED
BACON D, 1988, V6, P219, J MOL GRAPHICS
BARBIS DP, 1992, V191, P301, VIROLOGY
BERNS KI, 1990, P1743, VIROLOGY
BROWN CS, 1992, V66, P6989, J VIROL
BROWN CS, 1994, V198, P477, VIROLOGY
CHANG SF, 1992, V66, P6858, J VIROL
CHAPMAN MS, 1993, V2, P459, PROTEIN SCI
CHAPMAN MS, 1993, V194, P491, VIROLOGY
CHAPMAN MS, 1993, V194, P491, VIROLOGY
CORTES E, 1993, V74, P2005, J GEN VIROL
COTMORE SF, 1987, V33, P91, ADV VIRUS RES
DAVIES DR, 1988, V263, P541, J BIOL CHEM
DETURISO JAL, 1991, V72, P2445, J GEN VIROL
HARTMAN AB, 1988, V141, P932, J IMMUNOL

-more-

?

Display 6/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

ICENOGLE J, 1983, V127, P412, VIROLOGY
JONES TA, 1991, V47, P110, ACTA CRYSTALLOGR A
JONGENEEL CV, 1986, V59, P564, J VIROL
KAJIGAYA S, 1991, V88, P4646, P NATL ACAD SCI USA
KRAULIS PJ, 1991, V24, P946, J APPL CRYSTALLOGR
KURTZMAN G, 1989, V321, P519, NEW ENGL J MED
LANGEVELD JPM, 1993, V67, P765, J VIROL
LANGEVELD JPM, 1994, V68, P4506, J VIROL
LEE B, 1971, V55, P379, J MOL BIOL
MIYAMURA K, 1994, V91, P8507, P NATL ACAD SCI USA
PARRISH CR, 1991, V65, P6544, J VIROL
PARRISH CR, 1988, V163, P230, VIROLOGY
PATTISON JR, 1990, P1765, VIROLOGY

RIMMELZWAAN GF, 1990, V71, P2741, J GEN VIROL
ROSENFELD SJ, 1992, V89, P2023, J CLIN INVEST
ROSSMANN MG, 1989, V58, P533, ANNU REV BIOCHEM
ROSSMANN MG, 1988, V164, P373, VIROLOGY

-more-

?
Display 6/9/2 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

SATO H, 1991, V65, P1667, J VIROL
SATO H, 1991, V65, P5485, J VIROL
SHERIFF S, 1987, V84, P8075, P NATL ACAD SCI USA
SMITH TJ, 1990, V23, P141, J APPL CRYSTALLOGR
SMITH TJ, 1993, V67, P1148, J VIROL
SMITH TJ, 1993, V90, P7015, P NATL ACAD SCI USA
STRASSHEIM ML, 1994, V198, P175, VIROLOGY
STUDDARD MJ, 1990, P27, HDB PARVOVIRUSES
TATTERSALL P, 1980, P123, HDB PARVOVIRUSES
TRUYEN U, 1994, V200, P494, VIROLOGY
TSAO J, 1991, V251, P1456, SCIENCE
WIKOFF WR, 1994, V2, P595, STRUCTURE
WILSON IA, 1993, V3, P113, CURR OPIN STRUC BIOL
WU H, 1993, V233, P231, J MOL BIOL
YOSHIMOTO K, 1991, V65, P7056, J VIROL

- end of record -

?
Display 6/9/3 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

0247255 DBR Accession Number: 2000-01745
Chimeric virus-like particle formation of **adeno**-associated virus - the capsids of which are composed of three proteins, VP1, VP2, and VP3
AUTHOR: Hoque M; Shimizu N; Ishizu K; Yajima H; Arisaki F; Suzuki K; Watanabe H; +Handa H
CORPORATE AFFILIATE: Tokyo-Inst.Technol. Nat.Inst.Infec.Dis.Tokyo
CORPORATE SOURCE: Frontier Collaborative Research Laboratory, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama, 226-8501, Japan. email:hhanda@bio.titech.ac.jp
JOURNAL: Biochem.Biophys.Res.Commun. (266, 2, 371-76) 1999
ISSN: 0006-291X CODEN: BBRCA9
LANGUAGE: English
ABSTRACT: **Adeno**-associated virus (AAV) capsids are composed of three proteins, **VP1**, **VP2**, and **VP3** which have a common amino acid sequence, being expressed from **different** initiation codons on the same open reading frame. Although VP1 is necessary for viral

-more-

?
Display 6/9/3 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.

infection, it is not essential for capsid formation. The capsid proteins VP2 and VP3 are sufficient for capsid formation, but their functions are poorly understood. To investigate the roles of the capsid proteins in capsid formation, a baculo virus protein expression system was used to produce virus-like particles (VLPs). Varying the ratios of VP2 and VP3 did not affect VLP formation. Further, their physical properties were equivalent to those of empty wild-type particles. The function of VP3 was studied by fusing a peptide tag, FLAG, to its N-terminus. This chimeric viral protein, in combination with VP2, could assemble into VLPs, indicating that the chimerism of VP3 did not affect the VLP formation. It may be possible to utilize AAV VLP as vectors of a broad range of drugs since the fusion of the VP3 N-terminus with defined molecules could impose distinct physical properties onto the internal environment of the VLP. (21 ref)

DESCRIPTORS: **adeno**-associated virus, capsid formation, baculo virus protein expression system, virus-like particle chimerism, appl. drug delivery parvo virus gene therapy (Vol.19, No.4)

-more-

?
Display 6/9/3 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2005 Thomson Derwent & ISI. All rts. reserv.
SECTION: PHARMACEUTICALS-Clinical Genetic Techniques; GENETIC ENGINEERING AND FERMENTATION-Nucleic Acid Technology (D7,A1)

- end of record -

? e au=zolotukhin, sergei

Ref	Items	Index-term
E1	3	AU=ZOLOTUKHIN, SB
E2	49	*AU=ZOLOTUKHIN, SERGEI
E3	1	AU=ZOLOTUKHIN, SERGEJ N.
E4	1	AU=ZOLOTUKHIN, SERGEJ NIKOLAEVICH
E5	1	AU=ZOLOTUKHIN, SERGEY F.
E6	6	AU=ZOLOTUKHIN, SF
E7	2	AU=ZOLOTUKHIN, ST
E8	2	AU=ZOLOTUKHIN, SV
E9	2	AU=ZOLOTUKHIN, T. M.
E10	2	AU=ZOLOTUKHIN, V.
E11	51	AU=ZOLOTUKHIN, V. A.
E12	8	AU=ZOLOTUKHIN, V. D.

Enter P or PAGE for more

? e au=zolotukhin sergei

Ref	Items	Index-term
E1	85	*AU=ZOLOTUKHIN SERGEI
E2	2	AU=ZOLOTUKHIN SERGEY F
E3	9	AU=ZOLOTUKHIN SI
E4	11	AU=ZOLOTUKHIN SP
E5	6	AU=ZOLOTUKHIN ST
E6	8	AU=ZOLOTUKHIN SV
E7	1	AU=ZOLOTUKHIN SY
E8	1	AU=ZOLOTUKHIN SYU
E9	2	AU=ZOLOTUKHIN T A
E10	1	AU=ZOLOTUKHIN T E
E11	4	AU=ZOLOTUKHIN T F
E12	1	AU=ZOLOTUKHIN TE

Enter P or PAGE for more

? s e1 and AAV?
85 AU=ZOLOTUKHIN SERGEI
20190 AAV?
S7 33 AU='ZOLOTUKHIN SERGEI' AND AAV?
? rd s7
>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.
...completed examining records
S8 12 RD S7 (unique items)
? s s8 not py>2002
>>>One or more prefixes are unsupported
>>> or undefined in one or more files.
12 S8
19607638 PY>2002
S9 7 S8 NOT PY>2002
? d s9/3/1-7
Display 9/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2005 BIOSIS. All rts. reserv.

0014094591 BIOSIS NO.: 200300053310
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors.
AUTHOR: **Zolotukhin Sergei**; Potter Mark; Zolotukhin Irene; Sakai Yoshihisa; Loiler Scott; Fraites Thomas J; Chiodo Vince A; Phillipsberg Tina; Muzyczka Nicholas; Hauswirth William W; Flotte Terance R; Byrne Barry J; Snyder Richard O (Reprint
AUTHOR ADDRESS: Powell Gene Therapy Center, College of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL, 32610-0266, USA**USA
AUTHOR E-MAIL ADDRESS: rsnyder@gtc.ufl.edu
JOURNAL: Methods (Orlando) 28 (2): p158-167 October 2002 2002
MEDIUM: print
ISSN: 1046-2023 _(ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?
Display 9/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011726011 BIOSIS NO.: 199800520258
Construction of recombinant adeno-associated virus (**AAV**)
BOOK TITLE: Methods in Molecular Medicine; Hepatitis C protocols
AUTHOR: Reiser Markus (Reprint); **Zolotukhin Sergei**
BOOK AUTHOR/EDITOR: Lau J Y-N (Editor)
AUTHOR ADDRESS: Med. Universitaetsklin., Knappschattskrankenhaus, Bochum, Germany**Germany
SERIES TITLE: Methods in Molecular Medicine 19 p533-538 1998
MEDIUM: print
BOOK PUBLISHER: Humana Press Inc. {a}, Suite 808, 999 Riverview Drive, Totowa, New Jersey 07512, USA
ISBN: 0-89603-521-2
DOCUMENT TYPE: Book; Book Chapter
RECORD TYPE: Citation
LANGUAGE: English

- end of record -

?
Display 9/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011253087 BIOSIS NO.: 199800047334
Green fluorescent protein as a reporter for gene transfer studies in the cochlea
AUTHOR: Lalwani Anil K (Reprint); Han Jay J; Walsh Bong J; **Zolotukhin Sergei**; Muzyczka Nicholas; Mhatre Anand N
AUTHOR ADDRESS: Lab. Molecular Otol., Epstein Lab., Dep. Otolaryngol.-Head Neck Surg., Univ. Calif. San Francisco, 350 Parnassus Ave., Suite 210, San Francisco, CA 94117, USA**USA
JOURNAL: Hearing Research 114 (1-2): p139-147 Dec., 1997 1997
MEDIUM: print
ISSN: 0378-5955
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?
Display 9/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011179430 BIOSIS NO.: 199799813490
Recombinant adeno-associated virus type 2 replication and packaging is

. entirely supported by a herpes simplex virus type 1 amplicon expressing rep and cap
AUTHOR: Conway James E; **Zolotukhin Sergei**; Muzyczka Nicholas; Hayward Gary S; Byrne Barry J (Reprint
AUTHOR ADDRESS: Dep. Mol. Genetics Microbiol., Gene Therapy Cent., University Florida, PO Box 100296, Gainesville, FL 32610-0296, USA**USA
JOURNAL: Journal of Virology 71 (11): p8780-8789 1997 1997
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?
Display 9/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0011009999 BIOSIS NO.: 199799644059
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus
AUTHOR: Flannery John G (Reprint); **Zolotukhin Sergei**; Vaquero M Isabel; Lavail Matthew M; Muzyczka Nicholas; Hauswirth William W
AUTHOR ADDRESS: Sch. Optometry Neuroscience Group, Univ. California, Berkeley, CA 94720, USA**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 94 (13): p6916-6921 1997 1997
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?
Display 9/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0010868576 BIOSIS NO.: 199799502636
Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells
AUTHOR: Gnatenko Dmitri (Reprint); Arnold Thomas E; **Zolotukhin Sergei** ; Nuovo Gerard J; Muzyczka Nicholas; Bahou Wadie F
AUTHOR ADDRESS: Div. Hematol., HSCT15-040 SUNY, Stony Brook, NY 11794-8151, USA**USA
JOURNAL: Journal of Investigative Medicine 45 (2): p87-98 1997 1997
ISSN: 1081-5589
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?
Display 9/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0010259090 BIOSIS NO.: 199698726923
Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats
AUTHOR: Ryan John H; **Zolotukhin Sergei**; Muzyczka Nicholas (Reprint
AUTHOR ADDRESS: Dep. Mol. Genet. Microbiol., Coll. Medicine, Univ. Fla., P.O. Box 100266 JHMHSC, Gainesville, FL 32610, USA**USA
JOURNAL: Journal of Virology 70 (3): p1542-1553 1996 1996
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

- end of record -

?
?
?